This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CV Sciences, Inc. (CVSI) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 50% and 6.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CV Sciences, Inc. (CVSI) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 0% and 15.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
VAXART, INC. (VXRT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
VAXART, INC. (VXRT) delivered earnings and revenue surprises of -9.52% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of 0% and 307.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Lags Q4 Earnings Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of -5.26% and 1.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why CV Sciences, Inc. (CVSI) Looks Ripe for Bottom Fishing
by Zacks Equity Research
CV Sciences, Inc. (CVSI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
CV Sciences, Inc. (CVSI) Reports Break-Even Earnings for Q3
by Zacks Equity Research
CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 100.00% and -7.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will CV Sciences, Inc. (CVSI) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CV Sciences, Inc. (CVSI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 0.00% and 0.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will CV Sciences, Inc. (CVSI) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will CV Sciences, Inc. (CVSI) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CV Sciences, Inc. (CVSI) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -350.00% and -22.52%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will CV Sciences, Inc. (CVSI) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CV Sciences, Inc. (CVSI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -50.00% and -11.93%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will CV Sciences, Inc. (CVSI) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate CV Sciences, Inc. (CVSI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Small-Cap ETFs & Stocks Outperformed Last Week
by Sweta Killa
Given the improvements in domestic economy, small-cap stocks led the way higher last week.
CV Sciences Inc (CVSI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CV Sciences Inc (CVSI) delivered earnings and revenue surprises of -66.67% and 37.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate CV Sciences, Inc. (CVSI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CV Sciences, Inc. (CVSI) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
CV Sciences, Inc. (CVSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CV Sciences, Inc. (CVSI) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -250.00% and -18.91%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: CV Sciences, Inc. (CVSI) Q4 Earnings Expected to Decline
by Zacks Equity Research
CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CV Sciences, Inc. (CVSI) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -300.00% and -32.29%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate CV Sciences, Inc. (CVSI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CV Sciences, Inc. (CVSI) Meets Q2 Earnings Estimates
by Zacks Equity Research
CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 0.00% and -3.44%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?